Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Serum and Urinary Metabolomics Reflect the Early Stages of De Novo Metabolic Syndrome After Liver Transplant: A 2-Center Longitudinal Study.

Clinical and translational gastroenterology·2026
Same author

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
Same author

Clinical and Demographic Determinants of Adherence to Digital Monitoring in Cirrhosis: A Prospective Cohort Analysis.

Research square·2026
Same author

Fast but safe: speeding up clinical pathways in solid organ transplantation. An overview.

Minerva anestesiologica·2026
Same author

Frailty 1 year after liver transplant is associated with long-term mortality: From the Functional Assessment in Liver Transplantation (FrAILT) Study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

The Liver Frailty Index improves mortality risk prediction for GEMA-Na.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same journal

Cardiogenic shock - toward phenotype-directed, precision management.

Current opinion in critical care·2026
Same journal

The future of critical care nutrition: from calorie counting to precision personalized metabolism therapy.

Current opinion in critical care·2026
Same journal

Editorial introduction.

Current opinion in critical care·2026
Same journal

Generative artificial intelligence for outcome prediction in critical care: the future is now?

Current opinion in critical care·2026
Same journal

Feeding under support in critical care illness: metabolic and nutritional management during extracorporeal membrane oxygenation and continuous renal replacement therapy.

Current opinion in critical care·2026
Same journal

Multinational collaborations in critical care research: feasible and useful?

Current opinion in critical care·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Renal interactions in liver dysfunction and failure.

Elizabeth C Verna1, Gebhard Wagener

  • 1Division of Digestive and Liver Diseases, Department of Medicine, Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, NY 10032-3784, USA.

Current Opinion in Critical Care
|February 21, 2013
PubMed
Summary
This summary is machine-generated.

This review highlights advances in understanding liver-kidney interactions, focusing on new biomarkers for acute kidney injury (AKI) in liver disease and transplantation. Improved management of kidney dysfunction is key for better patient outcomes.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Area of Science:

  • Hepatology and Nephrology
  • Translational Medicine

Background:

  • The intricate relationship between liver and kidney function is critical in disease states.
  • Renal dysfunction is a common complication in chronic liver disease and post-liver transplantation.

Purpose of the Study:

  • To review recent advances in understanding liver-kidney pathophysiology.
  • To examine novel biomarkers for acute kidney injury (AKI) in cirrhosis and liver transplantation.
  • To discuss new treatments for hepatorenal syndrome (HRS) and kidney dysfunction in transplant recipients.

Main Methods:

  • Literature review of recent studies on liver-kidney interactions.
  • Analysis of novel biomarkers for AKI and HRS.
  • Evaluation of current therapeutic strategies for kidney dysfunction in liver disease and transplantation.

Main Results:

  • The renin-angiotensin system's effect on hepatic fibrosis and the gut's role in AKI were investigated.
  • Neutrophil gelatinase-associated lipocalin shows promise in predicting AKI and HRS.
  • Advances include vasopressin analogs for HRS and kidney-sparing immunosuppression post-transplantation.

Conclusions:

  • Enhanced understanding of liver-kidney physiology may lead to targeted therapies.
  • Early diagnosis of AKI with biomarkers can guide treatment.
  • Optimizing kidney disease management is vital for long-term outcomes in liver transplant patients.